Tumor‐specific GNAQ/GNA11 mutations in the cell‐free DNA were determined using deep amplicon sequencing and the proportion of mutant versus wild‐type sequences was used as a measure for the proportion of tumor‐derived DNA in the plasma of the patients. Here, GNAQ is linked to neoplasm.